2025
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.Peer-Reviewed Original ResearchConceptsMogamulizumab-associated rashConcomitant steroid useSezary syndromeAdvanced diseaseMycosis fungoidesSteroid useResponse to mogamulizumabProportion of patientsPercentage of patientsTreatment of patientsConcomitant steroidsRelapsed/refractory patientsLong-term responseMogamulizumabNext treatmentPatient characteristicsPatientsLymphopeniaVorinostatPatient responseFungoidesPFSMycosisSyndromeTreatmentPhase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Munoz-Couselo E, Rivas A, Sandhu S, Long G, Sanmamed M, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Fernandez A, Grob J, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgräber V, Kraxner A, Keshelava N, Bechter O. Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma. Cancer Research Communications 2025, 5: 358-368. PMID: 39895413, PMCID: PMC11848832, DOI: 10.1158/2767-9764.crc-24-0601.Peer-Reviewed Original ResearchConceptsPhase Ib studyMetastatic melanomaFibroblast activation proteinSafety profileLack of clinical activityPhase Ib clinical studySafety run-in cohortAntitumor activityProgression-free survivalCD8 T cellsInfusion-related reactionsElevated alanine aminotransferaseQ3W dosingOpen-labelPembrolizumabT cellsAdverse eventsClinical studiesIb studyClinical activityExtension cohortMelanomaPatientsAlanine aminotransferaseInduction phaseType 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Vesely M, Christensen S. Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention. Journal Of Clinical Investigation 2025, 135: e188018. PMID: 39744952, PMCID: PMC11684797, DOI: 10.1172/jci188018.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaThymic stromal lymphopoietinType 2 immunityActinic keratosisAK lesionsTh2 cellsPrevent cutaneous squamous cell carcinomaRecruitment of Th2 cellsCSCC preventionSquamous cell carcinomaMouse model of skin carcinogenesisModel of skin carcinogenesisDamage-associated molecular patternsKeratinocyte cell deathAntitumor immunityTopical calcipotriolSkin cancer preventionCell carcinomaPaired biopsiesPrecursor lesionsSkin carcinogenesisUnaffected skinMouse modelCancer preventionPremalignant keratinocytesDermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyDermatofibrosarcomaHumansMedical OncologyNeoplasm Recurrence, LocalSkin NeoplasmsConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Foss F, Kim Y, Prince H, Akilov O, Querfeld C, Seminario-Vidal L, Fisher D, Kuzel T, Yannakou C, Geskin L, Feldman T, Sokol L, Allen P, Dang N, Cabanillas F, Wong H, Ooi C, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Journal Of Clinical Oncology 2024, 43: 1198-1209. PMID: 39700456, PMCID: PMC11949209, DOI: 10.1200/jco-24-01549.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaTreatment-emergent adverse eventsTime to responseT-cell lymphomaTumor burdenRefractory cutaneous T-cell lymphomaEnd pointsEfficacy end pointCapillary leak syndromePrimary efficacy analysisSecondary end pointsHuman interleukin-2Unmet medical needMedian DoRSystemic therapyInfusion reactionsOpen-labelDenileukin diftitoxEfficacy analysisAdverse eventsInterleukin-2Safety resultsQ1-Q3PatientsResponse rateDNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, Parrish E, Hao H, Lin L, Kenney J, Ilelaboye G, Kostrzewa C, Kuan P, Busam K, Lezcano C, Lee T, Hernando E, Googe P, Ollila D, Moschos S, Gorlov I, Amos C, Ernstoff M, Cust A, Wilmott J, Scolyer R, Mann G, Vergara I, Ko J, Rees J, Yan S, Nagore E, Bosenberg M, Rothberg B, Osman I, Lee J, Saenger Y, Bogner P, Thompson C, Gerstenblith M, Holmen S, Funchain P, Brunsgaard E, Depcik-Smith N, Luo L, Boyce T, Orlow I, Begg C, Berwick M, Thomas N, Berwick M, Luo L, Boyce T, Reynolds A, Wiggins C, Thomas N, Conway K, Edmiston S, Ollila D, Hao H, Parrish E, Googe P, Moschos S, Corcoran D, Vondras A, Tsai Y, Lin L, Shen R, Begg C, Arora A, Seshan V, Reiner A, Kostrzewa C, Busam K, Orlow I, Lezcano C, Kenney J, Sadeghi K, O'Connell K, Ilelaboye G, Parmar H, Leong S, Corrales S, Scolyer R, Cust A, Wilmott J, Mann G, Shang P, Burke H, Ferguson P, Jakrot V, Lee T, Hernando E, Osman I, Hanniford D, Argibay D, Moran U, Heguy A, Ramaswami S, Amos C, Gorlov I, Zhu D, Ernstoff M, Bogner P, Lee J, Rees J, Yan S, Gerstenblith M, Thompson C, Ko J, Funchain P, Ngo P, Bosenberg M, Gould Rothberg B, Panse G, Saenger Y, Fullerton B, Holmen S, Colman H, Brunsgaard E, Wada D, Nagore E, Manrique-Silva E, Requena C, Traves V, Millan-Esteban D, Rainka M. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology 2024, 8: e2400375. PMID: 39509669, PMCID: PMC11737429, DOI: 10.1200/po-24-00375.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCpG island methylator phenotypePrimary melanomaBreslow thicknessMethylation classClinicopathological characteristicsN stageRisk of melanoma-related deathLow methylationStage IIRetrospective case-control studyCutaneous primary melanomaHigher AJCC stagePrimary cutaneous melanomaHigher N stageMelanoma-related deathDNA methylation classDied of melanomaMitotic indexCase-control studyIII patientsClinicopathological factorsCpG island hypermethylationPrognostic significanceAJCC stageAchieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).
Xu Y, Lim Y, Bordeaux J, Aasi S, Alam M, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Grekin R, Mark L, Nehal K, Nghiem P, Olino K, Patel T, Scott J, Shaha A, Srivastava D, Schmults C. Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 39536442, DOI: 10.6004/jnccn.2024.7037.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellGuideline AdherenceHumansMargins of ExcisionMohs SurgeryPractice Guidelines as TopicSkin NeoplasmsConceptsMargin assessmentCell carcinomaNCCN GuidelinesHigh-risk basal cell carcinomasCutaneous squamous cell carcinomaDeep margin assessmentMohs micrographic surgerySquamous cell carcinomaBasal cell carcinomaNonmelanoma skin cancerMicrographic surgeryDermatofibrosarcoma protuberansCure rateOptimal patient outcomesUninvolved tissueAccurate resectionSkin cancerPatient outcomesNCCNCarcinomaHistological visualizationMarginal surfacesTissueCCPDMAResectionTrends in Invasive Melanoma Thickness in Norway, 1983-2019.
Rimal R, Robsahm T, Green A, Ghiasvand R, Rueegg C, Bassarova A, Gjersvik P, Weiderpass E, Aalen O, Møller B, Perrier F, Veierød M. Trends in Invasive Melanoma Thickness in Norway, 1983-2019. Acta Dermato Venereologica 2024, 104: adv26110. PMID: 39221835, DOI: 10.2340/actadv.v104.26110.Peer-Reviewed Original ResearchConceptsLong-term incidence trendsCancer Registry of NorwayIncidence time trendsTumor thicknessCancer RegistryIncidence trendsBirth cohortTime trendsPrevention strategiesMelanoma occurrenceAge groupsMelanoma RegistryT categoryMelanoma thicknessT1 melanomasPathology reportsYounger patientsAnatomical sitesIncreased incidenceMelanomaSex differencesTumorIncidencePatientsMenStatins Inhibit Cutaneous Squamous Cell Carcinoma Cells
HACKETT A, COHEN A, RUTENBERG T, HODAK E, MOYAL L, ATZMONY L. Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells. Acta Dermato Venereologica 2024, 104: 25097. PMID: 39185545, PMCID: PMC11367778, DOI: 10.2340/actadv.v104.25097.Peer-Reviewed Original ResearchGP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorFemalegp100 Melanoma AntigenHumansImmunohistochemistryMaleMelanomaMiddle AgedSkin NeoplasmsConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistryPrognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin NeoplasmsConceptsMacrophage migration inhibitory factorImmune checkpoint inhibitionD-dopachrome tautomeraseExpression of macrophage migration inhibitory factorDrivers of tumor progressionInflammatory cell markersPatient tumor samplesPatient survival outcomesMigration inhibitory factorStatistically significant differenceCheckpoint inhibitionImmune therapyPrognostic valueSurvival outcomesResistant melanomaGene expressionImproved survivalRetrospective studyInflammatory markersTumor progressionCell markersTumor samplesClinical evidenceMelanomaBulk RNA sequencingDeveloping expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome
Lukowiak T, Cahn B, Samie F, Leffell D, Oro A, Kibbi N, Kheterpal M, Babakoohi S, Khushalani N, Stephenson A, Ma M, Shi V, Ahmed A, Koza E, Haq M, Yi M, Nadir U, Yoo S, Brieva J, Lucas J, Haber R, Alam M. Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome. Archives Of Dermatological Research 2024, 316: 453. PMID: 38967654, DOI: 10.1007/s00403-024-03157-z.Peer-Reviewed Original ResearchChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart reviewMelanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trialsThe Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill R, Blokx W, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker D, Redpath M, Scolyer R, Shea C, Spatz A, Tron V, Xu X, Yeh I, Yun S, Zembowicz A, Gerami P. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 708-718. PMID: 38590014, DOI: 10.1097/pas.0000000000002226.Peer-Reviewed Original ResearchConceptsDesmoplastic melanomaMelanocytic neoplasmsNext-generation sequencingInterobserver agreementDiagnostic accuracyHematoxylin and eosin sectionsImpact of next-generation sequencingDiagnostic scenariosMetastatic diseaseDesmoplastic tumorsMelanocytic tumorsMelanoma casesMelanoma geneticsFleiss' multirater kappaAccurate diagnosisNeoplasmsMelanomaAncillary toolDegree of improvementMultirater kappaDiagnosisGenomic findingsTumorGenome sequencing resultsPathologistsBRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms
Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lowe L, Massi D, Mihic-Probst D, Parker D, Scolyer R, Shea C, Zembowicz A, Yun S, Blokx W, Barnhill R. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 538-545. PMID: 38525831, DOI: 10.1097/pas.0000000000002194.Peer-Reviewed Original ResearchMeSH KeywordsDiagnosis, DifferentialHumansMelanomaNevusNevus, Epithelioid and Spindle CellProto-Oncogene Proteins B-rafSkin NeoplasmsAtezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study
de Sousa L, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas E, Cho W, Wistuba I, Yao J, Woodman S, Halperin D, Ferrarotto R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncology 2024, 151: 106747. PMID: 38460288, DOI: 10.1016/j.oraloncology.2024.106747.Peer-Reviewed Original ResearchVulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Kendra K, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Espinosa S. Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 117-135. PMID: 38503056, DOI: 10.6004/jnccn.2024.0013.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaFemaleGenital Neoplasms, FemaleHumansPaget Disease, ExtramammarySkin NeoplasmsVulvar NeoplasmsConceptsNCCN Clinical Practice GuidelinesVulvar cancerClinical practice guidelinesCell carcinomaHistologically squamous cell carcinomaSystemic therapy optionsSquamous cell carcinomaBasal cell carcinomaExtramammary Paget's diseasePractice guidelinesVerrucous carcinomaGynecologic malignanciesHuman papillomavirusVulvar neoplasiaTherapy optionsPaget's diseaseInflammatory conditionsRisk factorsCigarette smokingCarcinomaCancerIncreasing ageHistologyNCCNVulvarAllogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
Goyal A, Foss F. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma. Expert Review Of Anticancer Therapy 2024, 24: 41-58. PMID: 38224371, DOI: 10.1080/14737140.2024.2305356.Peer-Reviewed Original ResearchConceptsDonor lymphocyte infusionTotal body irradiationT-cell lymphomaCAR-T cell therapyCutaneous T-cell lymphomaT-cell therapySezary syndromeAllo-HSCTT cellsLymphocyte infusionCAR-TMycosis fungoidesAllogeneic hematopoietic stem cell transplantationCAR-T cell persistenceReduced-intensity conditioning regimensHematopoietic stem cell transplantationAdvanced stage MFTemporary disease controlTreatment of MF/SSCAR-T therapyInduce complete remissionCurative treatment optionStem cell transplantationNonmalignant T cellsTime of transplantationSequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Ascierto P, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci P, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro M, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao M, Minisini A, De Placido S, Sanmamed M, Mallardo D, Paone M, Vitale M, Melero I, Grimaldi A, Giannarelli D, Dummer R, Sileni V, Palmieri G. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature Communications 2024, 15: 146. PMID: 38167503, PMCID: PMC10761671, DOI: 10.1038/s41467-023-44475-6.Peer-Reviewed Original ResearchConceptsOverall survivalSurvival outcomesNoncomparative phase II trialTotal progression-free survivalLong-term survival outcomesMEK inhibitionBRAF/MEK inhibitionFirst-line treatment approachFirst-line treatment optionBRAF/MEK inhibitorsT-lymphocyte antigen-4Cell death protein 1BRAFV600-mutant melanomaDual checkpoint blockadeFirst-line immunotherapyMetastatic BRAF V600Serum interferon gammaPhase II trialProgression-free survivalDeath protein 1BRAFV600-mutant metastatic melanomaLow baseline levelsBiomarker analysisCombination BRAFSequential immunotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply